Cost-Effectiveness Evaluation and Its Role in Japan NHI Drug Pricing

Japan has spent decades refining its National Health Insurance (NHI) drug pricing system, and the introduction of formal cost-effectiveness evaluation (CEA) represents one of the most significant structural changes in recent history. For global pharma market access teams, understanding where CEA fits within Japan's pricing framework — and how its scope is evolving — is now a prerequisite for accurate Japan launch planning. Getting this wrong can mean a pricing outcome that is materially lower than modeled.

Background: Why Japan Introduced CEA

Japan's NHI drug pricing system historically relied on comparator-based and cost-of-production methodologies, with premiums for clinical usefulness determined through qualitative assessment. While clinically grounded, this approach offered limited tools for evaluating whether the incremental clinical benefit of a new drug justified its incremental price — particularly for high-cost therapies entering the market.

As drug expenditure rose and high-cost specialty medicines (CAR-T therapies, gene therapies, and targeted oncology agents) began listing on the NHI price list, the Chuikyo (Central Social Insurance Medical Council) recognized that the existing framework needed a health economic dimension. Japan formally introduced a cost-effectiveness evaluation system for NHI drug pricing in 2019, with initial implementation covering a limited number of high-cost products.

The system draws on the incremental cost-effectiveness ratio (ICER) concept familiar from other HTA markets like the UK's NICE or Canada's CADTH, but it is embedded within Japan's own pricing architecture in a distinct way — functioning as an adjustment to an already-established NHI price rather than as a gate-keeping mechanism that can block coverage.

How Japan's CEA Process Works in Practice

Once a drug reaches the NHI price list, it may be selected for cost-effectiveness evaluation if it meets certain criteria — primarily related to high annual cost per patient, typically above a threshold of approximately ¥1.5 million per patient per year (though MHLW guidance has been evolving and the threshold has been subject to discussion). The selection is made by Chuikyo and is not initiated by the manufacturer.

After selection, the manufacturer submits a cost-effectiveness dossier, which MHLW's advisory body — supported by independent academic experts — reviews. The analysis uses Japanese-specific data where available, and QALY-based ICER thresholds guide the assessment. If the drug's ICER exceeds acceptable thresholds (generally discussed around ¥5–10 million per QALY, though these figures are not rigidly codified in all cases), the NHI price may be adjusted downward.

Crucially, this adjustment comes on top of the standard price revision cycle — it is an additional price reduction mechanism layered onto the existing framework. For high-cost biologics and specialty therapies, this has produced material price reductions in several real-world cases.

FY2026 Reforms: Industry Concerns and Policy Trajectory

The FY2026 NHI Drug Price Reform process has brought CEA back to the forefront of industry debate. MHLW and Chuikyo have been discussing expansion of the CEA system — both in terms of the number of products subject to evaluation and the rigor of the assessment.

In December 2025, a joint statement from the Japan Pharmaceutical Manufacturers Association (JPMA), PhRMA (representing US research-based pharma), and EFPIA (the European equivalent) called on MHLW to proceed cautiously with any CEA expansion. The statement argued that premature or aggressive expansion, without robust independent verification of the methodology, risks undermining Japan's attractiveness as an early launch market and disadvantaging patients who depend on timely access to innovative therapies.

Industry concerns center on several specific issues: the reliance on Japanese-specific utility values that may not adequately reflect patient preferences for rare or ultra-rare disease populations, the treatment of subgroup data in multi-indication products, and the cumulative price impact when CEA reductions are layered on top of Market Expansion Repricing and annual price revisions.

MHLW's published framework for FY2026 suggests the agency is aware of these concerns but intends to gradually extend CEA's scope, with a focus on ensuring methodological consistency rather than pulling back from the program.

What CEA Means for Launch Pricing Strategy

For market access teams, the practical implication is clear: any product likely to meet the cost-per-patient threshold for CEA selection should have a Japan health economics strategy in place well before NHI listing — not after.

This means generating or adapting health utility data early in the clinical development program, ideally using Japanese patient populations or validated mapping methods. It means understanding the ICER thresholds likely to be applied in the relevant disease area and modeling the probability of price adjustment under different clinical profile scenarios. And it means engaging with MHLW proactively to understand the timeline and scope of any likely CEA selection.

Teams that treat CEA as a post-listing issue tend to find themselves responding reactively to a price adjustment rather than having shaped the evidence package to minimize its impact. The methodological details that drive ICER calculations — utilities, comparators, time horizons, discount rates — are not trivial, and Japan's approach has nuances that differ from European HTA bodies even where the conceptual framework is similar.

Monitoring Japan Drug Pricing Changes in Real Time

Given the complexity of Japan's multi-layered pricing environment — launch price, CEA adjustment, Market Expansion Repricing, annual revisions, and PMP eligibility — market access teams need reliable data infrastructure to track how prices actually evolve over a product's NHI lifecycle.

NHI Price Wire provides comprehensive, searchable access to all 17,000+ NHI-listed drug prices, updated with each revision cycle. Whether you are benchmarking the pricing impact of a past CEA evaluation, identifying comparable products for a new submission, or tracking how your competitor's listed price has moved over time, NHI Price Wire puts that data at your fingertips. Start a free trial and see how it can sharpen your Japan pricing intelligence.